NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.

This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

More From The Market Online
A physician in a white lab coat consulting a patient.

WELL Health expands clinical businesses in Canada with acquisitions

WELL Health Technologies (TSX:WELL) reveals updates related to its Canadian clinic business, boasting significant growth across the country.
doctor pointing finger to CT scans

Quantum BioPharma to run multiple sclerosis progression study

Quantum BioPharma (CSE:QNTM) will conduct a study observing disease progression in patients with primary progressive multiple sclerosis.
Two people sitting across from each other with their hands folded

Safety Strips’ U.S. expansion in partnership with Greenlane Holdings

Safe Supply is committed to transforming healthcare through innovative medical technologies and AI-powered solutions.
Rexall drug store in Toronto.

McKesson to sell Rexall and Well.ca to private equity firm

McKesson (NYSE:MCK), a diversified healthcare stock, will sell its Rexall and Well.ca businesses to Birch Hill Equity Partners.